MRT coming soon to a plant near you - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MRT coming soon to a plant near you


Pharmaceutical Technology Europe
Volume 21, Issue 10


Fedra Pavlou
Well, the summer's well and truly behind us and Madrid beckons for this year's CPhI Worldwide. I am looking forward to my October visit to the Spanish capital, not only for the fine weather, fresh tapas and good wine of course, but because this will be my first visit to the world's largest exhibition on pharmaceutical ingredients. Not only do we attend these events to keep updated on cutting edge technologies and processes as well as the latest developments in your industry, but they provide the ideal forum for us to gain feedback from our readers first hand. As always, the Pharmaceutical Technology Europe (PTE) team will be exhibiting at the event (stand 6G42) so please do stop by to say hello and to let us know what you think of your PTE. We look forward to meeting you there.

In this month's issue of PTE, we investigate the role of microreactor technology (MRT) in the continuous, commercial scale production of pharmaceuticals. This really is a fascinating technology and, although its use in the pharma industry has been largely limited to small-scale, laboratory settings, we fully believe that we will be hearing a lot more about MRT over the coming years. In fact, not only are some of the big names in pharma already endorsing it (GlaxoSmithKline being one of the first to use MRT for multi kg-scale projects some 4–5 years ago) but, according to the experts that we spoke with this month, many of the pharma giants are now investigating the feasibility of the technology for some of their new projects. Lack of data, knowledge and perhaps confidence, as well as the relative immaturity of the technology in this setting have deterred widespread uptake so far; however, even the FDA has encouraged manufacturers to seek alternative manufacturing methods. The US agency has emphasised the benefits of continuous processing to improve efficiency, manage variability, reduce waste and reduce the incidence of the scale-up problems associated with batch manufacturing. So, as the curtain of confidentiality is lifted and more data is published touting the benefits of MRT in commercial scale pharmaceutical production, confidence in the technology is sure to grow and widespread uptake will inevitably follow.




Turning our attention online, I'm hoping that by now you will have had the opportunity to take a look at our brand new website, http://www.pharmtech.com/. We do hope that you find it useful but, as always, I would welcome your thoughts on it, so please do feel free to email me. Our LinkedIn group is another way of keeping in touch with us so do take this as an invitation to join and connect with our growing group of experts by visiting http://www.pharmtech.com/linkedin.

Best wishes,
Fedra Pavlou, Editor-in-Chief

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here